Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 951 to 975 of 1139 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
951 occurrence viral mRNA export from host cell nucleus (GO:0046784) 2192: Influenza A Virus production increased
952 occurrence virus maturation (GO:0019075) 2192: Influenza A Virus production increased
953 occurrence suppression by virus of host cytokine production (GO:0046775) 2180: Immune mechanisms antagonized by viral proteins
954 occurrence virus induced gene silencing (GO:0009616) 2180: Immune mechanisms antagonized by viral proteins
955 occurrence modulation by virus of host immune response (GO:0075528) 2180: Immune mechanisms antagonized by viral proteins
956 occurrence viral budding from plasma membrane (GO:0046761) 2193: Influenza A Virus (IAV) budding
957 occurrence transmission of virus (GO:0019089) 2194: Influenza A Virus (IAV) shedding and transmission
958 increased Breast carcinoma (HP:0003002) VEGF-A complex (GO:1990150) 1376: Increase, angiogenesis
959 increased Breast carcinoma (HP:0003002) BRCA1-A complex (GO:0070531) 1971: Increased, tumor growth
960 increased Hepatic steatosis (HP:0001397) 459: Increase, Liver steatosis
961 increased hepatocyte (CL:0000182) None
962 increased lipid oxidation (GO:0034440) polyunsaturated fatty acid (CHEBI:26208) 1445: Increase, Lipid peroxidation
963 increased Abnormality of the testis (HP:0000035) Testis (FMA:7210) 2206: Increased, histomorphological alteration of testis
964 decreased viable offspring quantity (VT:1000181) 2147: Decreased, Viable Offspring
965 decreased hormone biosynthetic process (GO:0042446) None
966 abnormal animal organ formation (GO:0048645) epididymis (UBERON:0001301) 2212: Epididymal agenesis
967 decreased hormone biosynthetic process (GO:0042446) 17beta-Hydroxy-2-oxa-5alpha-androstan-3-one (CHEBI:79436) 1613: Decrease, dihydrotestosterone (DHT) levels
968 abnormal animal organ formation (GO:0048645) urethra (UBERON:0000057) 2213: Impaired, urethral tube closure
969 increased specification of animal organ position (GO:0010159) urethral opening (UBERON:0010418) None
970 increased increased apoptosis (MP:0006042) 1513: General Apoptosis
971 increased gene expression (GO:0010467) lipid (CHEBI:18059) None
972 abnormal specification of animal organ position (GO:0010159) urethral opening (UBERON:0010418) None
973 abnormal animal organ development (GO:0048513) 1616: Malformation, cryptorchidism - maldescended testis
974 occurrence epithelial to mesenchymal transition (GO:0001837) Epithelial cell (FMA:66768) 1457: Epithelial Mesenchymal Transition
975 disrupted peroxisome proliferator activated receptor signaling pathway (GO:0035357) 2227: Disrupted PPAR isoform nuclear signaling